does semaglutide cause vision loss A new study suggests patients taking — the active ingredient in Ozempic and Wegovy — may be at higher risk of developing an eye condition that can blindness. Non-arteritic anterior Study: Ozempic linked to eye
Description
If abdominal pain is severe, persistent, or accompanied by fever, it could indicate pancreatitis, a rare but serious complication

You should keep track of weight loss, changes in your blood sugar, and any side effects that come up
Pen prescribing tips If patients receive a starter kit that includes four 0.25 mg Wegovy pens, check the samples given box in their electronic health record Write prescription for 0.5 mg For those who do not receive a sample, write a prescription for 0.25 mg Check to make sure the dispense quantity unit of measure is mL only Always choose semaglutide (Wegovy ) for the intended indication when searching the product database When titrating patients up to 7.2 mg, you may need to select Wegovy HD For patients who tolerate the 2.4 mg dosage for at least 4 weeks and additional weight reduction is clinically indicated, the dosage may be increased to a maximum dosage of 7.2 mg subcutaneously once weekly Consider treatment response and tolerability when selecting the maintenance dosage Consider, when appropriate, writing a physical script for your patients to fill at their pharmacy of choice Encourage your patients to check in throughout their dose-escalation schedule to assess progress and tolerability After your patients reach their maintenance dose, you can consider a 3-month Rx Important to Remember: A new prescription is required for each dose strength Integrated needle means no separate Rx or co-pay A prior authorization may be required if patient is using commercial insurance Example Rx for the 0.25 mg starting dose: How to prescribe the once-daily Wegovy pill 1 * The Wegovy pill comes in 4 different strengths

That single fact determines everything about how it responds to heat

The STEP TEENS study [107] evaluated the effect of SMG (versus placebo) in adolescents with obesity
